ValuEngine Upgrades Coherus Biosciences (NASDAQ:CHRS) to “Sell”
Coherus Biosciences (NASDAQ:CHRS) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Monday, ValuEngine reports.
Other analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Coherus Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Monday. TheStreet raised shares of Coherus Biosciences from a “d+” rating to a “c-” rating in a report on Friday, March 20th. Credit Suisse Group reaffirmed a “buy” rating and issued a $36.00 target price on shares of Coherus Biosciences in a research note on Thursday, March 5th. SunTrust Banks began coverage on shares of Coherus Biosciences in a research report on Friday, April 17th. They set a “buy” rating and a $26.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Coherus Biosciences in a report on Friday, May 8th. Two equities research analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Coherus Biosciences presently has a consensus rating of “Buy” and an average price target of $30.88.
Coherus Biosciences stock traded down $0.45 during trading hours on Monday, hitting $17.25. 2,192,900 shares of the stock were exchanged, compared to its average volume of 1,541,435. The stock has a market capitalization of $1.22 billion, a P/E ratio of 8.80 and a beta of 2.05. The business’s 50-day moving average is $17.46 and its two-hundred day moving average is $17.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.18 and a current ratio of 3.32. Coherus Biosciences has a 12 month low of $10.86 and a 12 month high of $23.91.
In other news, Director Mary T. Szela sold 54,997 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.58, for a total value of $966,847.26. Following the transaction, the director now owns 14,997 shares of the company’s stock, valued at approximately $263,647.26. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Vincent R. Anicetti sold 5,000 shares of Coherus Biosciences stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.57, for a total value of $77,850.00. The disclosure for this sale can be found here. Insiders sold a total of 268,925 shares of company stock worth $4,627,867 in the last ninety days. Insiders own 15.86% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Private Capital Group LLC grew its position in shares of Coherus Biosciences by 244.7% during the 1st quarter. Private Capital Group LLC now owns 2,382 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,691 shares during the period. Meeder Asset Management Inc. boosted its stake in Coherus Biosciences by 378.7% during the 4th quarter. Meeder Asset Management Inc. now owns 2,269 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 1,795 shares during the last quarter. Great West Life Assurance Co. Can acquired a new position in Coherus Biosciences during the fourth quarter valued at approximately $64,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Coherus Biosciences by 27.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,617 shares of the biotechnology company’s stock valued at $75,000 after purchasing an additional 990 shares in the last quarter. Finally, Advisor Group Holdings Inc. acquired a new stake in Coherus Biosciences in the first quarter worth $82,000.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Featured Story: What is total return in investing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.